AZ nabs breakthrough shot at FDA for new Lynparza use; Top cancer centers urge more HPV vaccine use; NICE lends backing to biosim adoption;

@FiercePharma: No obvious China baby bump for J&J as one-child policy ends. FiercePharmaAsia article | Follow @FiercePharma

@EricPFierce: Novartis is revamping its manufacturing after having disposed of 25 plants. FiercePharmaManufacturing article | Follow @EricPFierce

@CarlyHFierce: ICYMI: U.K. cost watchdog nixes pricey biologics for moderate rheumatoid arthritis. Article | Follow @CarlyHFierce

> AstraZeneca's ($AZN) new ovarian cancer drug Lynparza got a "breakthrough" designation from the FDA for a new use in prostate cancer. Report

> Top cancer centers in the U.S. urged broader use of human papillomavirus vaccines such as GlaxoSmithKline's ($GSK) Cervarix and Merck & Co.'s ($MRK) Gardasil to prevent cancer linked to the virus. Report

> Biosimilars got a boost in Britain this week as England's cost-effectiveness watchdog said patients needing expensive biologic meds should start with "the least expensive drug." Report

> GlaxoSmithKline's consumer business in Nigeria got a buyout offer for its drinks bottling and distribution business there. Report

> Abbott Laboratories ($ABT) posted lower-than-expected quarterly sales and forecast 2016 earnings below expectations. Report

Medical Device News

@FierceMedDev: Israeli VC backed by Philips and Teva looking to invest $26M in promising med tech startups. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Sony, Carlyle Group, KKR among bidders for Toshiba's imaging unit, expected to fetch $3B+. Article | Follow @VarunSaxena2

@EmilyWFierce: Dog flu sweeps the U.S. with two more confirmed cases in Washington state. FierceAnimalHealth story | Follow @EmilyWFierce

> Investor urges J&J to spin out poor-performing device, consumer businesses. Report

> HeartWare succumbs to activist investors, calls off planned Valtech purchase. Story

> CMS draws blood, says Theranos poses 'immediate jeopardy to patient health.' Article

Biotech News

@FierceBiotech: UT Southwestern team IDs next-gen approach to fighting pancreatic cancer. FierceBiotechResearch article | Follow @FierceBiotech

@JohnCFierce: Turn out the lights, the party is over: Gov't finds Theranos lab poses 'immediate jeopardy to patient safety.' CNBC article | Follow @JohnCFierce

> Neos wins FDA approval for a melts-in-your-mouth take on Adderall for ADHD. Article

> The top 10 (possible) blockbusters that (might) launch this year. More

> Venetoclax grabs third FDA 'breakthrough' for blood cancer. Report

CRO News

> PRA recruits a U.K. marketing firm to help it reach more patients. Report

> In the midst of cuts, Parexel signs new research deal. More

> Parexel dims its revenue expectations despite a solid quarter. Story

> Icon launches new tech with promise to simplify adaptive trials. News

> BioClinica notches up another deal, this time with EPS. Article

Pharma Manufacturing News

> Lilly closing two animal health manufacturing plants picked up from Novatis. Article

> Baxter recalls saline, other products, contaminated by cardboard, cloth and skin. News

> Novartis revamping manufacturing after hiving off 25 plants. More

> GSK production coming up short for meningitis B vax, causing some shortages. Item

> Recipharm wrapping up its $105M deal for Indian sterile injectables maker Nitin. Article

Pharma Asia News

> India's Supreme Court allows Cipla move in Roche patent case. News

> Sino Biopharma's asset management deal drawing negative reviews. Report

> 3SBio buys a larger stake in CP Guojian Pharma for $150M. Story

> Novartis expects India's Sun to meet February U.S. generic Gleevec launch. More

> Another legal test for U.S. in case of Chinese scientists accused of stealing GSK secrets. Article

And Finally... One percent of U.S. doctors are responsible for a third of malpractice payments. Report

Suggested Articles

With drug-resistant bacteria on the rise, antibiotics have struggled to keep up. But with an FDA nod for Nabriva's Xenleta, some of that may change.

JAK drugs have run into safety issues, and if the label for AbbVie's Rinvoq is any indication, the FDA now believes those the issues are class-wide.

Rather than "we did the best we could," Vas Narasimhan, during an internal call with managers, said Novartis could have handled the Zolgensma crisis…